Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05273736 · ClinicalTrials.gov registry record · Phase 1

A BCT Intervention for Medication Adherence Among Individuals on Statins

A Phase 1 study of Medication Adherence, sponsored by Northwell Health.

Completed
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT05273736: Completed Phase 1 study of Medication Adherence, sponsored by Northwell Health.

NCT05273736 is a Phase 1 study of Medication Adherence that has completed, run by Northwell Health. The registered enrollment target is 42 participants, below the 1,656-participant average among 52 other Medication Adherence trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05273736, a Phase 1 study of Medication Adherence, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among participants on primary prevention statin therapy who are at elevated risk for cardiovascular disease (CVD). The intervention will be comprised of 5 BCTs which have previously shown to be effective on increasing health behaviors: Goal Setting, Action Planning, Self-Monitoring, Feedback, and Prompts/Cues. Participants will complete a 2-week run-in period where medication adherence levels will be measured using a smart pill bottle and physical activity (PA) will be measured using Fitbit wearable devices. Then 42 participants will be randomized into 14 cohorts of 3 participants each for the intervention period. During the intervention period, participants will receive a multi-BCT intervention, the length of which varies between 1 and 10 weeks depending on the assigned dose. Assignment to doses will utilize a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) methodology to adjust the dose for each cohort based on the results from the previous cohort. After the intervention, there will be a 2-week follow-up period. The MED will be defined as the smallest BCT dose (defined by weeks of intervention) associated with 80% of participants having a 20% medication adherence increase between the run-in and the follow-up periods.

Primary Outcome

Participant medication adherence increase will be assessed between run-in and follow-up periods using the smart pill bottle. A successful adherence increase is defined as average daily adherence to statin medications in the 2-week follow-up period being higher by 20% or more than in the 2-week run-in period. The minimum effective dose (MED) will be defined as the smallest BCT dose duration associated with 80% of participants receiving that dose having a successful statin adherence increase betwe

Conditions Studied

Interventions

  • BEHAVIORAL 5 Behavioral Change Techniques

Study Locations (1)

New York

  • Institute of Health System Science - New York

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2022-07-21
Est. Completion 2024-10-07
Phase Phase 1
Northwell Health

370 total trials

What the finished NCT05273736 record still lists

NCT05273736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,656-participant average among 52 other Medication Adherence trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Medication Adherence appearing as the primary indexed condition, and to 1 intervention - of which 5 Behavioral Change Techniques is the first listed.

NCT05273736 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05273736 about?

NCT05273736 is a clinical study titled "A BCT Intervention for Medication Adherence Among Individuals on Statins". The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among participants on primary prevention statin therapy who are at elevated risk for cardiovascular disease (CVD). The i...

What is the current status of trial NCT05273736?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-07-21. Estimated completion is 2024-10-07.

What conditions does trial NCT05273736 study?

This clinical trial studies the following conditions: Medication Adherence.

What interventions are being tested in trial NCT05273736?

The interventions under investigation include: 5 Behavioral Change Techniques (BEHAVIORAL).

Who is sponsoring clinical trial NCT05273736?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05273736 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Medication Adherence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05273736's enrollment target sits among peer trials

42 46th of 52 higher than 7 of 52 other Medication Adherence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Medication Adherence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05273736, the US trial registry maintained by the National Library of Medicine. NCT05273736 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.